Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	Propanc Biopharma, Inc. Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.	United States of America	PPCB
	ProQR Therapeutics N.V. Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.	United States of America	PRQR
$Protagenic Therapeutics, Inc.\new Logo$	Protagenic Therapeutics, Inc.\new Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.	United States of America	PTIX
	Protagonist Therapeutics, Inc Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.	United States of America	PTGX
	Protalix BioTherapeutics, Inc. Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.	United States of America	PLX
	Protara Therapeutics, Inc. Clinical-stage biotech developing cell therapies for cancer and rare diseases.	United States of America	TARA
	PROTEINA CO.,LTD. A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.	South Korea	468530
	PROTIA INC. Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.	South Korea	303360
	Psych Capital Plc A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.	United Kingdom	PSY
	PSYENCE BIOMEDICAL LTD. Developing natural psilocybin therapies for anxiety and depression in palliative care.	United States of America	PBM